1
|
Risinskaya N, Kozhevnikova Y, Gavrilina O, Chabaeva J, Kotova E, Yushkova A, Isinova G, Zarubina K, Obukhova T, Kulikov S, Julhakyan H, Sudarikov A, Parovichnikova E. Loss of Heterozygosity in the Tumor DNA of De Novo Diagnosed Patients Is Associated with Poor Outcome for B-ALL but Not for T-ALL. Genes (Basel) 2022; 13:genes13030398. [PMID: 35327952 PMCID: PMC8952291 DOI: 10.3390/genes13030398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 02/16/2022] [Accepted: 02/21/2022] [Indexed: 11/29/2022] Open
Abstract
Despite the introduction of new technologies in molecular diagnostics, one should not underestimate the traditional routine methods for studying tumor DNA. Here we present the evidence that short tandem repeat (STR) profiling of tumor DNA relative to DNA from healthy cells might identify chromosomal aberrations affecting therapy outcome. Tumor STR profiles of 87 adult patients with de novo Ph-negative ALL (40 B-ALL, 43 T-ALL, 4 mixed phenotype acute leukemia (MPAL)) treated according to the “RALL-2016” regimen were analyzed. DNA of tumor cells was isolated from patient bone marrow samples taken at diagnosis. Control DNA samples were taken from the buccal swab or the blood of patients in complete remission. Overall survival (OS) analysis was used to assess the independent impact of the LOH as a risk factor. Of the 87 patients, 21 were found with LOH in various STR loci (24%). For B-ALL patients, LOH (except 12p LOH) was an independent risk factor (OS hazard ratio 3.89, log-rank p-value 0.0395). In contrast, for T-ALL patients, the OS hazard ratio was 0.59 (log-rank p-value 0.62). LOH in particular STR loci measured at the onset of the disease could be used as a prognostic factor for poor outcome in B-ALL, but not in T-ALL.
Collapse
Affiliation(s)
- Natalya Risinskaya
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Yana Kozhevnikova
- School of Medicine, Lomonosov Moscow State University, 27-1, Lomonosovsky Prospect, 119991 Moscow, Russia;
| | - Olga Gavrilina
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Julia Chabaeva
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Ekaterina Kotova
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Anna Yushkova
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Galina Isinova
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Ksenija Zarubina
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Tatiana Obukhova
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Sergey Kulikov
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Hunan Julhakyan
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Andrey Sudarikov
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
- Correspondence:
| | - Elena Parovichnikova
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| |
Collapse
|
2
|
Parovichnikova E, Troitskaya V, Sokolov A, Gavrilina O, Akhmerzaeva Z, Kuzmina L, Kliasova G, Chabaeva J, Kulikov S, Bondarenko S, Baranova O, Samoilova O, Kaplanov K, Minaeva N, Savchenko V. Can Less Intensive Chemotherapy and an Autotransplant Cure Adult T-Cell Acute Lymphoblastic Leukemia? Acta Haematol 2019; 143:131-139. [PMID: 31597157 DOI: 10.1159/000502435] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2019] [Accepted: 07/30/2019] [Indexed: 11/19/2022]
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is a rare disease usually treated with intensive, high-dose consolidation chemotherapy followed by an allotransplant in a substantial number of patients. The data of the RALL-2009 study on 125 adult T-ALL patients suggest that similar total chemotherapy doses given less intensively over a longer interval without interruptions and with an auto- rather than an allotransplant produce outcomes like current more intensive protocols and an allotransplant: 9-year cumulative incidence of relapse (CIR), leukemia-free survival (LFS), and survival were 24% (95% CI 16-33%), 70% (95% CI 59-79%) and 62% (95% CI 51-72%). In a landmark analysis, subjects achieving a complete remission and receiving an autotransplant had a lower 9-year CIR (9% [95% CI 2-22%] vs. 29% [95% CI 16-43%]; p = 0.0076) and better LFS (91% [95% CI 79-98%] vs. 58% [95% CI 41-74%]; p = 0.0009) and survival (92% [95% CI 77-99%] vs. 60% [95% CI 44-77%]; p = 0.001) compared with subjects not receiving an autotransplant. In a multivariate analysis, white blood cells ≥100 × 109/L at study entry were significantly associated with worse LFS (HR = 2.842 [95% CI 1.131-7.143]; p = 0.0263) and survival (HR = 6.085 [95% CI 1.918-19.3]; p = 0.0022) because of more early deaths (HR = 2.42 [95% CI 1.04-5.67]; p = 0.041). Receiving an autotransplant correlated with a lower CIR (HR = 0.23 [95% CI 0.07-0.73]; p = 0.0136) and better LFS (HR = 0.27 [95% CI 0.08-0.85]; p = 0.0256) and survival (HR = 0.158 [95% CI 0.045-0.550]; p = 0.0037).
Collapse
Affiliation(s)
- Elena Parovichnikova
- National Research Center for Hematology of the Russian Ministry of Health, Moscow, Russian Federation,
| | - Vera Troitskaya
- National Research Center for Hematology of the Russian Ministry of Health, Moscow, Russian Federation
| | - Andrey Sokolov
- National Research Center for Hematology of the Russian Ministry of Health, Moscow, Russian Federation
| | - Olga Gavrilina
- National Research Center for Hematology of the Russian Ministry of Health, Moscow, Russian Federation
| | - Zalina Akhmerzaeva
- National Research Center for Hematology of the Russian Ministry of Health, Moscow, Russian Federation
| | - Larissa Kuzmina
- National Research Center for Hematology of the Russian Ministry of Health, Moscow, Russian Federation
| | - Galina Kliasova
- National Research Center for Hematology of the Russian Ministry of Health, Moscow, Russian Federation
| | - Julia Chabaeva
- National Research Center for Hematology of the Russian Ministry of Health, Moscow, Russian Federation
| | - Sergey Kulikov
- National Research Center for Hematology of the Russian Ministry of Health, Moscow, Russian Federation
| | - Sergey Bondarenko
- Clinical Research Institution of Pediatric Hematology and Transplantation under the Name of Raisa Gorbacheva, State Medical University, St. Petersburg, Russian Federation
| | - Olga Baranova
- National Oncology Research Center of the Russian Ministry of Health, Moscow, Russian Federation
| | - Olga Samoilova
- Hematology Department, Regional Clinical Hospital, Nijniy Novgorod, Russian Federation
| | | | - Natalia Minaeva
- Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agency, Kirov, Russian Federation
| | - Valeriy Savchenko
- National Research Center for Hematology of the Russian Ministry of Health, Moscow, Russian Federation
| |
Collapse
|